Latest Insulet News & Updates

See the latest news and media coverage for Insulet. We track all announcements, press releases, and industry mentions in real time, all in one place.

Insulet

Maker of tubeless insulin delivery systems

insulet.com

Headquarters: Acton, United States
Founded year: 2000
Company type: Public company
Number of employees: 1,000–5,500

Last updated Today

Latest news about Insulet

In short: Insulet grew revenue 33.9% in Q1 2026, launched several product updates, and addressed a manufacturing-related voluntary recall of Omnipod 5 pods.

Company announcements

June 4 Insulet

Insulet reveals new data for Omnipod 6 and closed-loop

The STRIVE pivotal trial and EVOLUTION 3 feasibility study show improved glucose control with fewer boluses.

May 26 Insulet

Insulet initiates voluntary correction for certain Omnipod pods

The correction addresses a manufacturing issue that could cause insulin under-delivery, affecting approximately 7 million pods globally.

May 6 Insulet

Insulet reports Q1 2026 results

Revenue reaches $761.7M, up 33.9%; raises full-year guidance. Launches Omnipod 5 in Middle East, updates algorithm.

May 4 Insulet

Insulet enrolls first participant in EVOLVE study

The pivotal trial tests a fully closed-loop automated insulin delivery system for type 2 diabetes, aiming for FDA submission in 2027.

Media coverage

Today MSN

This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations...

Today MSN

Why Insulet (PODD) is a top growth stock for the long term

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different...

June 20 Yahoo Finance

Insulet (PODD): New Data Shows Its Next-Gen System Delivers Far More Automated Insulin

Insulet Corporation (NASDAQ:PODD) is one of the most promising healthcare stocks according to Wall Street analysts. On June 6, Insulet Corporation (NASDAQ:PODD) released new clinical...

June 16 AD HOC NEWS

Insulet Stock (US45784P1012): Quarterly earnings and growth outlook in focus

Insulet is in focus as investors review its latest quarterly results, growth in its Omnipod insulin delivery franchise, and updated guidance under US-GAAP. The Nasdaq-listed...

Never miss news about Insulet

Track Insulet and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Insulet competitors & trending companies

Browse news for competitors to Insulet and other trending companies.